Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q4 2022
Institutional positions in Aligos Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- −13 vs. Q3 2022
- Shares held
- 26.5M
- −1.12M (−4.1%) vs. Q3 2022
- Total value
- $25.3M
- −$5.13M (−16.9%) vs. Q3 2022
- New holders
- 1
- 11 more added
- Sold out
- 14
- 14 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALGS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.2M |
| Q1 2026 | 35 | $20.6M |
| Q4 2025 | 41 | $26.2M |
| Q3 2025 | 33 | $26.0M |
| Q2 2025 | 37 | $19.5M |
| Q1 2025 | 35 | $27.1M |
| Q4 2024 | 34 | $64.5M |
| Q3 2024 | 27 | $14.7M |
| Q2 2024 | 49 | $16.6M |
| Q1 2024 | 49 | $45.3M |
| Q4 2023 | 40 | $30.1M |
| Q3 2023 | 36 | $19.2M |
| Q2 2023 | 41 | $25.5M |
| Q1 2023 | 46 | $23.9M |
| Q4 2022 | 39 | $25.3M |
| Q3 2022 | 52 | $30.4M |
| Q2 2022 | 60 | $36.0M |
| Q1 2022 | 76 | $68.4M |
| Q4 2021 | 71 | $390.4M |
| Q3 2021 | 68 | $483.9M |
| Q2 2021 | 58 | $550.5M |
| Q1 2021 | 52 | $612.4M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Aligos Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 18 | $0 | 0.00% | +5+38.5% | Added |
| Cubist Systematic Strategies, LLC | 3 | $3 | 0.00% | −23−88.5% | Reduced |
| Newbridge Financial Services Group, Inc. | 37 | $35 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 85 | $81 | 0.00% | −478−84.9% | Reduced |
| Wells Fargo & Company | 173 | $165 | 0.00% | +4+2.4% | Added |
| FMR LLC | 1,012 | $964 | 0.00% | −1−0.1% | Reduced |
| JPMorgan Chase & Co | 677 | $1.00K | 0.00% | −3,125−82.2% | Reduced |
| Morgan Stanley | 2,353 | $2.24K | 0.00% | −7,929−77.1% | Reduced |
| Federated Hermes, Inc. | 3,180 | $3.03K | 0.00% | +1,163+57.7% | Added |
| Advisor Group Holdings, Inc. | 8,000 | $8.00K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 16,420 | $15.6K | 0.00% | +16,420 | New |
| HarbourVest Partners LLC | 18,783 | $17.9K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 32,604 | $31.1K | 0.00% | 00.0% | Unchanged |
| Ergoteles LLC | 36,367 | $34.7K | 0.00% | −16,522−31.2% | Reduced |
| State Street Corp | 60,823 | $58.0K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 66,259 | $63.0K | 0.00% | −35,513−34.9% | Reduced |
| Deutsche Bank AG | 71,290 | $67.9K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 82,500 | $78.6K | 0.00% | −35,000−29.8% | Reduced |
| Citadel Advisors LLC | 86,278 | $82.2K | 0.00% | +12,983+17.7% | Added |
| Two Sigma Investments, LP | 90,418 | $86.2K | 0.00% | −34,008−27.3% | Reduced |
| Bridgeway Capital Management, LLC | 112,000 | $106.7K | 0.00% | +33,000+41.8% | Added |
| Geode Capital Management, LLC | 199,858 | $190.0K | 0.00% | +9,440+5.0% | Added |
| New York Life Investment Management LLC | 263,832 | $251.4K | 0.00% | +29,732+12.7% | Added |
| BlackRock Inc. | 307,449 | $293.0K | 0.00% | −210,110−40.6% | Reduced |
| Acadian Asset Management LLC | 334,704 | $318.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 371,319 | $354.0K | 0.00% | +39,188+11.8% | Added |
| Renaissance Technologies LLC | 532,260 | $507.0K | 0.00% | −198,338−27.1% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $708.3K | 0.31% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 905,896 | $863.2K | 0.00% | −11,140−1.2% | Reduced |
| Vanguard Group Inc | 1,013,496 | $965.8K | 0.00% | −76,496−7.0% | Reduced |
| Bank of America Corp | 1,150,148 | $1.09M | 0.00% | +2,006+0.2% | Added |
| Adage Capital Partners GP, L.L.C. | 1,473,278 | $1.40M | 0.00% | 00.0% | Unchanged |
| Newtyn Management, LLC | 1,500,000 | $1.43M | 0.29% | +500,000+50.0% | Added |
| Baker Bros. Advisors LP | 2,076,400 | $1.98M | 0.01% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 2,309,764 | $2.20M | 0.05% | −55,300−2.3% | Reduced |
| Versant Venture Management, LLC | 2,320,381 | $2.21M | 4.58% | 00.0% | Unchanged |
| Tang Capital Management LLC | 2,816,391 | $2.68M | 0.39% | +1,142,225+68.2% | Added |
| Vivo Capital, LLC | 3,547,030 | $3.38M | 0.41% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 3,948,360 | $3.76M | 0.11% | 00.0% | Unchanged |
| Novo Holdings A/S | 0 | $0 | 0.00% | −1,950,000−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −77,499−100.0% | Sold out |
| Oasis Management Co Ltd. | 0 | $0 | 0.00% | −45,797−100.0% | Sold out |
| Brinker Capital Investments, LLC | 0 | $0 | 0.00% | −37,981−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −31,568−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −19,400−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −16,031−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −14,043−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −11,999−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −10,513−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −8,062−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −667−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −115−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −372−100.0% | Sold out |